INTRODUCTION {#s1}
============

The number of people who will develop and die from cancer is expected to climb rapidly around the world \[[@R1]\]. In 2016, a total of 1,685,210 cases of cancer were newly diagnosed and 595,690 people died from cancer in the United States \[[@R2]\]. Meanwhile, approximately 4,292,000 new cancer cases and 2,814.000 cancer deaths were projected in China in 2015 \[[@R3]\]. It is imperative to deal with the rising cancer burden by taking full advantage of the knowledge embedded in cancer statistics, causes, and mechanisms and apply it to cancer prevention and screening \[[@R4]\]. Genetic-environmental interaction has been considered an essential factor in carcinogenesis \[[@R5]\]. Meanwhile, the roles of multiple genetic changes in influencing the evolution of cancer have been investigated over the years \[[@R6]\].

Recently, a number of investigations have been conducted to study the potential influence of *Telomerase reverse transcriptase* (*TERT*) and *cleft lip and palate transmembrane 1-like* (*CLPTM1L*) gene variation on cancer susceptibility. The *TERT* gene encodes the rate-limiting catalytic subunit of the telomerase enzyme that is vital to the maintenance of telomere DNA length, chromosomal stability, and cellular immortality \[[@R7]\]. *CLPTM1L*, encodes a protein linked to cisplatin resistance and associated with the susceptibility to cleft lip palate. *CLPTM1L* was found to be overexpressed in cisplatin-resistant ovarian cancer cells and to promote apoptosis in cisplatin-sensitive cells \[[@R8]\]. *TERT-CLPTM1L* genetic variants, including single nucleotide polymorphisms, have been reported by several genome-wide association studies (GWAS) to associate with the risk of multiple cancer types \[[@R9]--[@R11]\]. Among these polymorphisms, rs402710 (C \> T) and rs401681 (C \> T) have been widely studied for their potential effect on the susceptibility to cancer. Jiang et al. found that rs401681 polymorphism was associated with a decreased risk of lung cancer \[[@R12]\], but other studies found no association was found between rs401681 polymorphism and lung cancer risk \[[@R13], [@R14]\]. For the rs402710 polymorphism, Ito et al. observed remarkable effects on susceptibility in lung cancer \[[@R15]\], but the results were not repeated in other similar studies \[[@R16], [@R17]\]. We conducted a comprehensive meta-analysis of all relevant articles to provide a systematic and cumulative assessment of the association of *CLPTM1L* rs402710 and rs401681 polymorphisms and overall cancer risk.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

As shown in Figure [1](#F1){ref-type="fig"}, 176 publications were initially identified from PubMed and EMBASE electronic databases that met our inclusion and exclusion criteria. After title and abstract screening, 61 records were excluded. The remaining 115 full text articles were further assessed and 67 were further excluded for the following reasons: 1) 12 were meta-analyses; 2) 43 were irrelevant; and 3) 12 had insufficient information to calculate odds ratios (ORs) and 95% confidence intervals (95% CIs). Additionally, 3 relevant studies were also retrieved manually from the pool. In the end, 51 eligible articles were included in the final meta-analysis.

![Flow diagram of studies included in our meta-analysis](oncotarget-08-102446-g001){#F1}

The genotypic distribution of rs402710 and rs401681 polymorphisms in the controls in almost all of the studies followed Hardy-Weinberg equilibrium (HWE); four did not (Table [1](#T1){ref-type="table"}) \[[@R11], [@R17]--[@R19]\]. Since the genotypic distribution of other polymorphisms was in agreement with HWE in these four studies, the investigators decided to include them in the final analysis. Together, there were 26 articles with 28 studies including 30,770 cases and 34,089 controls for the rs402710 polymorphism \[[@R13], [@R15]--[@R39]\] and 38 articles with 48 studies including 67, 849 cases and 328, 226 controls for the rs401681 polymorphism (Table [1](#T1){ref-type="table"}) \[[@R9]--[@R12], [@R14], [@R16]--[@R18], [@R21], [@R23]--[@R25], [@R28], [@R29], [@R32], [@R34], [@R35], [@R37], [@R38], [@R40]--[@R58]\]. For the rs402710 polymorphism, 19 studies focused on lung cancer, 2 on bladder cancer, and the rest on other individual types of cancer. There were 21 studies conducted on Asian populations, 5 on Caucasians, and 2 on Africans. 15 were hospital-based, and 12 were population-based. One was nested. As to the rs401681 polymorphism, 20 studies focused on lung cancer, 5 on bladder cancer and pancreatic cancer, 4 on melanoma, 3 on basal cell carcinoma, 2 on esophageal cancer and squamous cell carcinoma, and 7 on other individual cancer types, which we grouped as "the others" for our analyses. 24 were conducted on Asians, 21 on Caucasians, 2 on Africans, and only one on mixed ethnicity. There were 19 studies with a hospital-based design, 21 with a population-based design, and 8 with a nested design.

###### Characteristics of case-control studies included in the current meta-analysis

  Surname                     Year   Country   Ethnicity   Cancer type         Control source   Genotyping method   Cases/Controls   HWE     
  --------------------------- ------ --------- ----------- ------------------- ---------------- ------------------- ---------------- ------- -------
  **rs402710 polymorphism**                                                                                                                  
  Zhou                        2016   China     Asian       ESCC                HB               MassArray           588              600     0.762
  Zhang                       2016   China     Asian       NPC                 HB               MassArray           855              1036    0.512
  Jin                         2016   China     Asian       Lung cancer         HB               MassArray           552              717     0.007
  Ge                          2016   China     Asian       Thyroid carcinoma   HB               MassArray           500              500     0.675
  Liu                         2015   China     Asian       Lung cancer         PB               MassArray           288              318     0.997
  Zhao                        2014   China     Asian       Lung cancer         HB               Taqman              951              954     0.502
  Xun                         2014   China     Asian       Lung cancer         HB               MassArray           227              300     0.795
  Liang                       2014   China     Asian       Lung cancer         HB               MassArray           308              309     0.670
  Zhao                        2013   China     Asian       Lung cancer         PB               SNPscan             784              782     /
  Lu                          2013   China     Asian       Lung cancer         HB               Taqman              604              1062    0.971
  Zheng                       2012   USA       African     Breast cancer       PB               Illumina            1509             1383    /
  Zhao                        2012   China     Asian       Glioma              HB               MassArray           452              486     0.308
  Wang                        2012   China     Asian       Cervical cancer     HB               Taqman              1022             1046    0.741
  Ren                         2012   China     Asian       Prostate cancer     HB               PCR-RFLP            251              273     0.210
  Ito                         2012   Japan     Asian       Lung cancer         HB               Taqman              716              716     0.712
  Chen                        2012   China     Asian       Lung cancer         PB               Taqman              193              228     0.016
  Bae                         2012   Korea     Asian       Lung cancer         PB               Melting curve       1094             1099    0.682
  Pande                       2011   USA       Caucasian   Lung cancer         HB               Illumina            1681             1235    /
  Jaworowska                  2011   Poland    Caucasian   Lung cancer         HB               Taqman              848              845     0.696
  Gago-Dominguez 1            2011   USA       African     Bladder cancer      PB               Taqman              471              528     0.109
  Gago-Dominguez 2            2011   USA       Asian       Bladder cancer      PB               Taqman              503              527     0.223
  Yoon                        2010   Korea     Asian       Lung cancer         PB               Taqman              1425             3011    0.356
  Truong 1                    2010   France    Caucasian   Lung cancer         PB               Taqman              8860             9198    0.961
  Truong 2                    2010   France    Asian       Lung cancer         PB               Taqman              1680             2117    0.828
  Liu                         2010   USA       Caucasian   Lung cancer         PB               Affymetrix          194              214     /
  Hsiung                      2010   China     Asian       Lung cancer         Nested           Illumina            2659             2844    0.001
  Zienolddiny                 2009   Norway    Caucasian   Lung cancer         PB               Taqman              356              432     0.787
  Jin                         2009   China     Asian       Lung cancer         HB               PCR-RFLP            1199             1329    0.578
  **rs401681 polymorphism**                                                                                                                  
  Zhang                       2016   China     Asian       NPC                 HB               MassArray           1852             2008    0.832
  Jin                         2016   China     Asian       Lung cancer         HB               MassArray           554              695     0.411
  Liu                         2015   China     Asian       Lung cancer         PB               MassArray           292              319     0.696
  Gibbs                       2015   USA       Caucasian   Melanoma            PB               MassArray           1187             2409    0.512
  Campa                       2015   Germany   Caucasian   Pancreatic cancer   PB               Illumina            1857             4048    0.482
  Zhang                       2014   China     Asian       Lung cancer         HB               Taqman              366              364     0.097
  Zhang                       2014   China     Asian       Bladder cancer      HB               PCR--LDR            367              420     0.683
  Yin                         2014   China     Asian       Esophageal cancer   HB               PCR--LDR            604              664     0.365
  Xun                         2014   China     Asian       Lung cancer         HB               MassArray           224              299     0.819
  Su                          2014   China     Asian       HCC                 HB               Taqman              201              210     0.337
  Llorca-Cardenosa            2014   Spain     Caucasian   Melanoma            HB               Taqman              956              722     0.263
  Liu                         2014   China     Asian       Pancreatic cancer   PB               Taqman              766              821     0.263
  Liang                       2014   China     Asian       Lung cancer         HB               MassArray           309              308     0.631
  Wang                        2013   China     Asian       Lung cancer         HB               HRM                 492              486     0.076
  Sun                         2013   China     Asian       Lung cancer         HB               MassArray           400              200     0.942
  Myneni                      2013   China     Asian       Lung cancer         HB               MassArray           350              441     0.668
  Ma                          2013   China     Asian       Bladder cancer      HB               MassArray           177              920     0.044
  Li                          2013   China     Asian       Lung cancer         HB               Taqman              464              536     0.865
  Ke                          2013   China     Asian       Lung cancer         PB               Taqman              602              1060    0.939
  Jiang 1                     2013   China     Asian       Lung cancer         HB               Taqman              726              860     0.805
  Jiang 2                     2013   China     Asian       Esophageal cancer   HB               Taqman              753              860     0.805
  Zheng                       2012   USA       African     Breast cancer       PB               Illumina            1509             1383    /
  Zhao                        2012   China     Asian       Glioma              HB               MassArray           983              1024    /
  Lan                         2012   USA       Asian       Lung cancer         Nested           Illumina            5382             4452    /
  Chen                        2012   China     Asian       Lung cancer         PB               Taqman              195              228     0.016
  Bae                         2012   Korea     Asian       Lung cancer         PB               Melting curve       1086             1079    0.162
  Willis                      2012   USA       Caucasian   Pancreatic cancer   HB               Illumina            390              149     /
  Rizzato                     2011   Germany   Caucasian   Pancreatic cancer   PB               AS-PCR              661              1267    0.949
  Pande                       2011   USA       Caucasian   Lung cancer         HB               Illumina            1681             1235    /
  Nan 1                       2011   USA       Caucasian   Melanoma            PB               Taqman              208              809     0.497
  Nan 2                       2011   USA       Caucasian   SCC                 PB               Taqman              266              809     0.497
  Nan 3                       2011   USA       Caucasian   BCC                 PB               Taqman              283              809     0.497
  Gago-Dominguez 1            2011   USA       African     Bladder cancer      PB               Taqman              472              554     0.686
  Gago-Dominguez 2            2011   USA       Asian       Bladder cancer      PB               Taqman              500              529     0.292
  Yoon                        2010   Korea     Asian       Lung cancer         PB               Taqman              1425             3011    0.217
  Petersen                    2010   USA       Mixed       Pancreatic cancer   Nested           Illumina            3532             3642    /
  Liu                         2010   USA       Caucasian   SCCHN               PB               Taqman              1079             1115    0.775
  Liu                         2010   USA       Caucasian   Lung cancer         PB               Affymetrix          194              214     /
  Zienolddiny                 2009   Norway    Caucasian   Lung cancer         PB               Taqman              341              431     0.366
  Stacey 1                    2009   Iceland   Caucasian   Melanoma            Nested           Illumina            3843             41963   /
  Stacey 2                    2009   Iceland   Caucasian   SCC                 PB               Illumina            1103             35824   /
  Stacey 3                    2009   Iceland   Caucasian   BCC                 Nested           Illumina            3468             38107   /
  Rafnar 1                    2009   Iceland   Caucasian   BCC                 Nested           Illumina            2565             29405   /
  Rafnar 2                    2009   Iceland   Caucasian   Lung cancer         Nested           Illumina            4265             34666   /
  Rafnar 3                    2009   Iceland   Caucasian   Bladder cancer      Nested           Illumina            4147             34988   /
  Rafnar 4                    2009   Iceland   Caucasian   Prostate cancer     Nested           Illumina            9473             37901   /
  Rafnar 5                    2009   Iceland   Caucasian   Cervical cancer     PB               Illumina            276              28890   /
  Wang                        2008   UK        Caucasian   Lung cancer         PB               Illumina            5023             5092    0.223

ESCC, esophageal squamous cell carcinoma; NPC, nasopharyngeal carcinoma; HCC, hepatocellular carcinoma; SCC, squamous cell carcinoma; BCC, basal cell carcinoma; SCCHN, squamous cell carcinoma of the head and neck; HB, hospital based; PB, population based; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; PCR--LDR, polymerase chain reaction--ligation detection reaction; HRM, high-resolution melt; AS-PCR, allele-specific polymerase chain reaction; HWE, Hardy-Weinberg equilibrium.

Meta-analysis results of the rs402710 polymorphism {#s2_2}
--------------------------------------------------

As shown in Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}, there was evidence of a significant association between the rs402710 polymorphism and overall cancer risk under all of the five genetic models \[homozygous (TT vs. CC): OR = 0.77, 95% CI = 0.70--0.84; heterozygous (CT vs. CC): OR = 0.89, 95% CI = 0.86--0.92; recessive (TT vs. CT+CC): OR = 0.81, 95% CI = 0.74--0.88; and dominant (CT+TT vs. CC): OR = 0.87, 95% CI = 0.83--0.91; as well as the allele comparison model (T vs. C): OR = 0.88, 95% CI = 0.84--0.92\]. In the stratification analysis by cancer type, a statistically significant association was identified with lung cancer \[homozygous (TT vs. CC): OR = 0.73, 95% CI = 0.67--0.79; heterozygous (CT vs. CC): OR = 0.88, 95% CI = 0.85--0.91; recessive (TT vs. CT+CC): OR = 0.77, 95% CI = 0.71--0.84; and dominant (CT+TT vs. CC): OR = 0.85, 95% CI = 0.82--0.88; as well as allele comparison model (T vs. C): OR = 0.85, 95% CI = 0.81--0.89\] and bladder cancer \[dominant (CT+TT vs. CC): OR = 0.83, 95% CI = 0.70--0.99; and allele comparison model (T vs. C): OR = 0.85, 95% CI = 0.75--0.98\]. In the subgroup analysis by ethnicity and control source, there was a statistically significant association found in the studies of Asians and Caucasians in the hospital-based and population-based studies under all genetic models.

###### Meta-analysis of the association between rs402710 and rs401681 polymorphisms and cancer risk

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                   No. of individuals   Homozygous              Heterozygous   Recessive   Dominant                  Allele                                                                                                                                   
  --------------------------- -------------------- ----------------------- -------------- ----------- ------------------------- ---------- ------ ----------------------- ---------- ------ ----------------------- ---------- ------ ----------------------- ---------- ------
  **rs402710 polymorphism**                                                                                                                                                                                                                                              

  All                         30770/34089          **0.77 (0.70--0.84)**   0.006          46.8        **0.89 (0.86--0.92)**     0.121      26.0   **0.81 (0.74--0.88)**   0.021      40.6   **0.87 (0.83--0.91)**   0.032      37.9   0.88 (0.84--0.92)       \< 0.001   65.8

   Asian                      16851/20254          **0.78 (0.69--0.88)**   0.002          53.6        **0.90 (0.86--0.94)**     0.070      34.0   **0.82 (0.73--0.91)**   0.008      48.5   **0.88 (0.83--0.94)**   0.017      44.6   0.90 (0.85--0.94)       0.002      54.3

   African                    1980/1911            0.87 (0.56--1.36)       /              /           0.89 (0.68--1.16)         /          /      0.92 (0.60--1.41)       /          /      0.89 (0.69--1.14)       /          /      0.98 (0.89--1.07)       0.435      0.0

   Caucasian                  11939/11924          **0.73 (0.66--0.80)**   0.634          0.0         **0.86 (0.82--0.92)**     0.661      0.0    **0.78**\               0.590      0.0    **0.84 (0.79--0.88)**   0.681      0.0    **0.76 (0.66--0.87)**   \< 0.001   82.8
                                                                                                                                                  **(0.72--0.86)**                                                                                                       

   Lung                       24619/27710          **0.73 (0.67--0.79)**   0.205          21.8        **0.88 (0.85--0.91)**     0.272      15.8   **0.77 (0.71--0.84)**   0.104      32.3   **0.85 (0.82--0.88)**   0.437      1.3    **0.85 (0.81--0.89)**   0.001      58.0

   Bladder                    974/1055             0.75 (0.55--1.01)       0.347          0.0         0.85 (0.71--1.03)         0.651      0.0    0.80 (0.60--1.08)       0.409      0.0    **0.83 (0.70--0.99)**   0.471      0.0    **0.85 (0.75--0.98)**   0.359      0.0

   Others                     5177/5324            0.98 (0.74--1.30)       0.009          67.7        0.97 (0.88--1.07)         0.096      46.5   0.97 (0.78--1.20)       0.065      51.8   0.99 (0.84--1.17)       0.011      66.5   0.99 \|(0.89--1.10)     0.004      68.6

   HB                         10754/11408          **0.81 (0.69--0.95)**   0.002          60.1        **0.91 \|(0.86--0.97)**   0.185      25.0   **0.84 (0.73--0.97)**   0.016      50.2   **0.90 (0.82--0.97)**   0.017      50.0   **0.90 (0.84--0.96)**   \< 0.001   64.6

   PB                         17357/19837          **0.73 (0.67--0.80)**   0.404          3.7         **0.87 (0.83--0.91)**     0.216      25.6   **0.78 (0.70--0.87)**   0.214      25.8   **0.84 (0.80--0.88)**   0.465      0.0    **0.86 (0.80--0.92)**   \< 0.001   71.6

   Mixed                      2659/2844            **0.74 (0.61--0.89)**   /              /           0.94 (0.84--1.05)         /          /      **0.76**\               /          /      **0.90 (0.81--0.99)**   /          /      **0.89 (0.82--0.96)**   /          /
                                                                                                                                                  **(0.63--0.91)**                                                                                                       

  **rs401681 polymorphism**                                                                                                                                                                                                                                              

  All                         67849/328226         **0.87 (0.76--0.98)**   \< 0.001       79.2        0.95 (0.88--1.01)         \< 0.001   64.7   **0.90**\               \< 0.001   73.0   0.93 (0.87--1.01)       \< 0.001   74.2   **0.93 (0.89--0.97)**   \< 0.001   88.8
                                                                                                                                                  **(0.81--0.99)**                                                                                                       

   Asian                      19070/21794          **0.76 (0.66--0.87)**   \< 0.001       58.9        **0.89 (0.83--0.96)**     0.018      42.9   **0.80**\               \< 0.001   57.5   **0.87 (0.81--0.93)**   0.004      49.7   **0.88 (0.84--0.93)**   0.001      55.1
                                                                                                                                                  **(0.71--0.92)**                                                                                                       

   Caucasian                  43266/300853         1.11 (0.90--1.37)       \< 0.001       86.3        1.05 (0.92--1.20)         \< 0.001   77.6   1.08 (0.93--1.24)       \< 0.001   78.4   1.07 (0.92--1.24)       \< 0.001   84.4   0.96 (0.90--1.02)       \< 0.001   93.3

   African                    1981/1937            0.71 (0.49--1.03)       /              /           0.88 (0.67--1.16)         /          /      0.77 (0.56--1.07)       /          /      0.83 (0.64--1.08)       /          /      0.95 (0.80--1.13)       0.081      67.1

   Lung                       24371/55976          **0.73 (0.66--081)**    0.220          22.4        **0.86 (0.81--0.92)**     0.316      12.0   **0.78 (0.70--0.88)**   0.072      36.5   **0.84 (0.80--0.88)**   0.600      0.0    **0.86 (0.84--0.89)**   0.292      13.0

   Melanoma                   6194/45903           **1.47(1.23--1.75)**    0.291          19.0        **1.24 (1.09--1.41)**     0.976      0.0    **1.29 \\**\            0.196      38.6   **1.31 (1.16--1.47)**   0.747      0.0    **1.19 (1.14--1.24)**   0.451      0.0
                                                                                                                                                  **(1.09--1.53)**                                                                                                       

   Pancreatic                 7206/9927            **1.41 (1.24--1.60)**   0.576          0.0         **1.17 (1.06--1.29)**     0.688      0.0    **1.27**\               0.299      17.2   **1.24 (1.13--1.36)**   0.898      0.0    **1.19 (1.14--1.24)**   0.978      0.0
                                                                                                                                                  **(1.12--1.45)**                                                                                                       

   Bladder                    5663/37411           **0.70 (0.56--0.87)**   0.491          0.0         0.89 (0.77--1.03)         0.990      0.0    **0.74 (0.61--0.91)**   0.445      0.0    **0.85 (0.74--0.97)**   0.949      0.0    **0.84 (0.81--0.88)**   0.871      0.0

   Esophageal                 1357/1524            0.82 (0.64--1.05)       0.395          0.0         0.83 (0.66--1.05)         0.135      55.2   0.90 (0.71--1.14)       0.693      0.0    0.83 (0.66--1.04)       0.121      58.4   0.88 (0.76--1.02)       0.186      42.8

   SCC                        1369/36633           0.82 (0.53--1.26)       /              /           1.26 (0.92--1.72)         /          /      0.71\                   /          /      1.13 (0.84--1.53)       /          /      0.93 (0.86--1.01)       0.733      0.0
                                                                                                                                                  (0.48--1.04)                                                                                                           

   BCC                        6316/68321           0.87 (0.60--1.27)       /              /           **0.71 (0.53--0.96)**     /          /      1.05 (0.75--1.48)       /          /      **0.76 (0.57--1.00)**   /          /      **0.82 (0.79--0.85)**   0.692      0.0

   Others                     13521/70523          0.86 (0.57--1.30)       0.007          79.6        1.03 (0.75--1.41)         0.002      84.6   0.88 (0.59--1.30)       0.006      80.2   1.01 (0.74--1.38)       0.001      85.9   **0.92 (0.85--1.00)**   \< 0.001   77.1

   HB                         11849/12401          **0.78 (0.66--0.94)**   \< 0.001       63.6        0.92 (0.84--1.01)         0.016      48.5   **0.81 (0.70--0.95)**   0.004      55.4   **0.90**\               0.002      58.3   **0.90 (0.84--0.97)**   \< 0.001   66.9
                                                                                                                                                                                            **(0.82--0.99)**                                                             

   PB                         19325/90701          0.94 (0.79--1.12)       \< 0.001       84.3        0.96 (0.87--1.06)         \< 0.001   73.5   0.96 (0.84--1.10)       \< 0.001   78.8   0.93\                   \< 0.001   81.0   0.95 (0.88--1.02)       \< 0.001   83.5
                                                                                                                                                                                            (0.87--1.01)                                                                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HB, hospital based; PB, population based; SCC, squamous cell carcinoma; BCC, basal cell carcinoma

![Forest plot of the association between *CLPTM1L* rs402710 polymorphism and overall cancer risk under the allele contrast model](oncotarget-08-102446-g002){#F2}

Meta-analysis results of rs401681 polymorphism {#s2_3}
----------------------------------------------

As shown in Table [2](#T2){ref-type="table"} and Figure [3](#F3){ref-type="fig"}, similar to the rs402710 polymorphism, a significant association between the rs401681 polymorphism and overall cancer risk was also observed \[homozygous (TT vs. CC): OR = 0.87, 95% CI = 0.76--0.98; recessive (TT vs. CT+CC): OR = 0.90, 95% CI = 0.81--0.99; and allele comparison model (T vs. C): OR = 0.93, 95% CI = 0.89--0.97\]. In the stratification analysis by cancer type, a decreased association was identified with lung cancer \[homozygous (TT vs. CC): OR = 0.73, 95% CI = 0.66--0.81; heterozygous (CT vs. CC): OR = 0.86, 95% CI = 0.81--0.92; recessive (TT vs. CT+CC): OR = 0.78, 95% CI = 0.70--0.88; and dominant (CT+TT vs. CC): OR = 0.84, 95% CI = 0.80--0.88; as well as allele comparison model (T vs. C): OR = 0.86, 95% CI = 0.84--0.89\], bladder cancer and basal cell carcinoma. On the contrary, there was an increased risk for melanoma \[homozygous (TT vs. CC): OR = 1.47, 95% CI = 1.23--1.75; heterozygous (CT vs. CC): OR = 1.24, 95% CI = 1.09--1.41; recessive (TT vs. CT+CC): OR = 1.29, 95% CI = 1.09--1.53; and dominant (CT+TT vs. CC): OR = 1.31, 95% CI = 1.16--1.47; as well as allele comparison model (T vs. C): OR = 1.19, 95% CI = 1.14--1.24\] and pancreatic cancer \[homozygous (TT vs. CC): OR = 1.41, 95% CI = 1.24--1.60; heterozygous (CT vs. CC): OR = 1.17, 95% CI = 1.06--1.29; recessive (TT vs. CT+CC): OR = 1.27, 95% CI = 1.12--1.45; and dominant (CT+TT vs. CC): OR = 1.24, 95% CI = 1.13--1.36; as well as allele comparison model (T vs. C): OR = 1.19, 95% CI = 1.14--1.24\]. When the analysis was stratified by ethnicity, there was a statistically significant association among Asians, but not in Caucasians or Africans. When the analysis was stratified by control source, there was a statistically significant association in the hospital-based studies, but not in population-based studies.

![Forest plot of the association between *CLPTM1L* rs401681 polymorphism and overall cancer risk under the allele contrast model](oncotarget-08-102446-g003){#F3}

Heterogeneity and sensitivity analyses {#s2_4}
--------------------------------------

Substantial heterogeneities were observed among all studies of the rs402710 polymorphism and cancer risk (homozygous: *p* = 0.006; recessive: *p* = 0.021; and dominant: *p* = 0.032; as well as allele comparison model: *p* \< 0.001), except for the heterozygous model (*p* = 0.121). As to the rs401681 polymorphism, we also observed considerable heterogeneities (homozygous: *p* \< 0.001; heterozygous: *p* \< 0.001; recessive: *p* \< 0.001; and dominant: *p* \< 0.001; as well as allele comparison model: *p* \< 0.001). So, the random-effects model was applied to generate crude ORs and 95% CIs. In addition, the leave-one-out sensitivity analysis indicated that no single study altered the corresponding pooled ORs and 95% CIs.

Publication bias {#s2_5}
----------------

The shape of our funnel plot did not reveal any evidence of obvious asymmetry for the rs402710 polymorphism (homozygous: *p* = 0.738; heterozygous: *p* = 0.291; recessive: *p* = 0.954; and dominant: *p* = 0.318; as well as allele comparison model: *p* = 0.946) and rs401681 polymorphism (homozygous: *p* = 0.264; heterozygous: *p* = 0.451; recessive: *p* = 0.114; and dominant: *p* = 0.564; as well as allele comparison model: *p* = 0.967).

DISCUSSION {#s3}
==========

The *CLPTM1L* gene encodes the CLPTM1-like protein which is highly expressed in cisplatin-resistant ovarian tumor cell lines and is associated with cisplatin-induced apoptosis \[[@R8]\]. This gene has also been demonstrated to be overexpressed in many other cancers \[[@R58]--[@R61]\]. Blockade of CLPTM1-like protein has been shown to inhibit K-Ras-induced lung tumorigenesis \[[@R61]\]. *CLPTM1L*, near the *TERT* gene, is located at chromosome 5p15.33 which is widely identified as a susceptibility region associated with several types of cancer \[[@R62]\]. Some common genetic variants of *TERT-CLPTM1L* are hypothesized to have an important role in initiation and development of many cancers, including lung, bladder, pancreatic, thyroid, and breast cancer.

To the best of our knowledge, the meta-analysis in this study is the largest to study the associations between *CLPTM1L* rs402710 (C\>T) and rs401681 (C\>T) polymorphisms and overall cancer risk. In this meta-analysis, based on the database of publications in respect of the rs402710 polymorphism and the rs401681 polymorphism, among which there are 26 articles with 28 studies including 30,770 cases and 34,089 controls for rs402710 polymorphism and 38 articles with 48 studies including 67,849 cases and 328,226 controls for rs401681 polymorphism respectively, we observed both rs402710 and rs401681 polymorphisms were significantly associated with a decreased overall cancer risk. In the stratification analysis, as to the rs402710 polymorphism, a statistically significant association was also identified for lung and bladder cancer. Likewise, the rs401681 polymorphism was significantly associated with a decreased risk for lung cancer, bladder cancer and basal cell carcinoma. Interestingly, an increased risk of melanoma and pancreatic cancer was found for the rs401681 polymorphism.

Up until now, there had been only one meta-analysis (in 2013) focusing on rs402710 and rs401681 polymorphisms and overall cancer risk \[[@R62]\]; which only enrolled seven studies with 4,667 cancer patients and 4,990 controls for the rs402710 polymorphism and eight studies with 6,867 cancer patients and 7,746 controls for the rs401681 polymorphism. The said study found that rs402710 (A\>G) and rs401681 (A\>G) polymorphisms were associated with an increased cancer risk. In other words, rs402710 (C\>T) and rs401681 (C\>T) polymorphisms were significantly associated with a decreased overall cancer risk. In the stratification analysis by cancer type, Li et al. \[[@R62]\] included a few studies and did further stratification analysis only for lung and bladder cancer. Such associations were also observed with lung cancer from the meta-analyses before 2014 \[[@R63]--[@R65]\]. Since then, at least 8 studies for the rs402710 polymorphism and 13 studies for the rs401681 polymorphism have been published investigating the association with overall cancer risk, most of which focused on lung cancer. As the largest study with the strongest statistical power so far, the current meta-analysis also observed an association between the rs401681 polymorphism and an increased risk for melanoma and pancreatic cancer, which had been found in other meta-analyses \[[@R66], [@R67]\]. This observation suggested that the rs401681 polymorphism could play different roles in different types of cancer.

Several limitations in our meta-analysis should be acknowledged. First, we only included the studies published in English, which may have missed publications in other languages. Second, in the stratification analysis by cancer type and ethnicity, the sample sizes are relatively small and may be insufficient, which may have diminished the statistical power. Third, due to the lack of raw information such as age, sex, body mass index, smoking habits, and alcohol consumption, this meta-analysis was conducted on the basis of unadjusted estimates. Therefore, larger and well-designed studies with different types of cancer and multiple ethnic with sufficient raw information are warranted to validate the findings of this study.

In conclusion, the meta-analysis in this study demonstrated that *CLPTM1L* gene rs402710 and rs401681 polymorphisms were associated with a decreased risk of various types of cancer, especially for lung cancer among Asians.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

PubMed and EMBASE electronic databases were screened for publications investigating the association between *CLPTM1L* polymorphisms and overall cancer risk published prior to May 1, 2017. The following search terms were used: "CLPTM1L", "5p15", "polymorphism", "variant", "cancer", "tumor" and "carcinoma". Additional relevant studies were also retrieved manually from all the relevant publications, including the eligible original publications and reviews. Only the latest or the largest study would be included in the final meta-analysis.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

All studies included in the current meta-analysis met the following criteria: (1) evaluating the association between *CLPTM1L* rs402710 and rs401681 polymorphisms and the risk of all types of cancer; (2) case-control or cohort studies; (3) published in English; (4) including sufficient data for genotype frequencies; and (5) providing sufficient data to calculate ORs and 95% CIs. Exclusion criteria include: (1) insufficient raw data; (2) meta-analyses, reviews and comments; (3) duplicates of previous publications; and (4) case-only studies. Studies that were departure from HWE in controls were also excluded, unless further evidence indicated that another polymorphism was in agreement with HWE.

Data extraction {#s4_3}
---------------

Two investigators extracted the following information from all the eligible studies independently: surname of the first author, publication year, country of origin, ethnicity, cancer type, control source, genotyping method, number of cases and controls, and genotype frequencies of cases and controls. Different ethnicities were stratified into Asian, African, and Caucasian. The source of controls was categorized as hospital-based and population-based studies. Any disagreements were discussed and resolved until the consensus was reached.

Statistical analysis {#s4_4}
--------------------

The strength of association between the *CLPTM1L* rs402710 and rs401681 polymorphisms and the risk of all types of cancer were assessed by the calculation of crude ORs and 95% CIs. Stratification analyses were further performed according to ethnicity, cancer type and control source. The pooled ORs and 95% CIs were estimated for rs402710 polymorphism under the homozygous (TT vs. CC), heterozygous (CT vs. CC), recessive (TT vs. CT+CC), and dominant (CT+TT vs. CC), as well as allele comparison model (T vs. C) and so was rs401681 polymorphism under the homozygous (TT vs. CC), heterozygous (CT vs. CC), recessive (TT vs. CT+CC), and dominant (CT+TT vs. CC), as well as allele comparison model (T vs. C).

The Chi square-based Q-test was applied to evaluate between-study heterogeneity. If the studies were found to have no heterogeneity (*p* \> 0.10), the fixed-effects model (the Mantel-Haensze method) was used \[[@R68]\]. Otherwise, the random-effects model (the DerSimonian and Laird method) was adopted \[[@R69]\]. Furthermore, heterogeneity was also identified with the I^2^ test \[[@R70]\]. The higher values suggest the greater degree of heterogeneity. Thus the publication bias was quantified by Begg\'s funnel plot and Egger\'s linear regression test \[[@R71]\].

All the statistical analyses were conducted using STATA software (version 12.0, STATA Corporation, College Station, TX) and were two-sided, with *P* values less than 0.05 as statistically significant.
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